-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Raises Price Target to $22

Benzinga·12/11/2025 11:33:43
Listen to the news
HC Wainwright & Co. analyst Sara Nik maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and raises the price target from $4 to $22.